Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / exhibit-h-regulatory-compliance.docx
exhibit-h-regulatory-compliance.docx
Parties
Penterra Pharmaceuticals Corp
Hargrove LLP
Dates
June 28, 2023
January 15, 2023
April 1, 2023
March 31, 2024
Amounts
$52,000
$75,000
$40,000
$1,500,000
$4,200,000
$25,000,000
$75,000,000
$10,000,000
$50,000,000
$25,000
Obligations
gov Identifier: NCT05928174 Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement
The term "Investigator" shall also include any replacement or additional investigator designated in accordance with the Protocol and the Agreement
Part 312 Sponsor represents, warrants, and covenants that it shall comply with all obligations imposed upon a sponsor of a clinical investigation under 21 C
Sponsor shall select Investigators who are qualified by training and experience as appropriate experts to investigate penterafenib in accordance with 21 C
Sponsor shall ensure adequate monitoring of the Study in accordance with 21 C
The monitoring plan shall be set forth in the Monitoring Plan appended to the CRO Master Services Agreement